Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.82 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.68 |
| ▸ | MMP1 | P03956 | 2/20 | 0.68 |
| ▸ | MMP2 | P08253 | 2/20 | 0.68 |
| ▸ | MMP3 | P08254 | 2/20 | 0.68 |
| ▸ | MMP9 | P14780 | 2/20 | 0.68 |
| ▸ | MMP13 | P45452 | 2/20 | 0.68 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218730 | 1.00 | ADAM17 (0.82) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL13218402 | 0.91 | ADAM17 (0.69) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8227095 | 0.90 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL12860681 | 0.90 | ADAM17 (0.82) | ADAM17 | |
| SCHEMBL12860682 | 0.90 | ADAM17 (0.82) | ADAM17 | |
| SCHEMBL12860703 | 0.90 | ADAM17 (0.83) | ADAM17 | |
| SCHEMBL12860705 | 0.89 | ADAM17 (0.82) | ADAM17 | |
| SCHEMBL5956211 | 0.88 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL8226987 | 0.88 | ADAM17 (0.78) | ADAM17 | |
| SCHEMBL5954960 | 0.88 | ADAM17 (0.78) | ADAM17ADAM10MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ADAM17 15/4885ADAM10 19/4885MMP1 21/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | ADAM17 15/4885ADAM10 19/4885MMP1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.